Table 2.
Progression risk of non-dysplastic Barrett’s metaplasia and low-grade dysplasia patients related to expression of p53, Ki67, and TLR5. Figures indicate the numbers of samples. Percentages are indicated in parentheses
| Non-progressive Barrett’s metaplasia | Progressive Barrett’s metaplasia | OR (95% CI) | Non-progressive low-grade dysplasia | Progressive low-grade dysplasia | OR (95% CI) | |
|---|---|---|---|---|---|---|
| Samples | n = 54 | n = 25 | n = 46 | n = 39 | ||
| p53 intensity | ||||||
| Normal expression* | 54 (100) | 24 (96) | 1 (Ref) | 38 (83) | 17 (44) | 1 (Ref) |
| Aberrant expression** | 0 (0) | 1 (4) | Non est | 8 (17) | 22 (56) | 6.7 (95% CI 1.8–24.6) |
| Overexpression** | 0 (0) | 0 (0) | 8 (17) | 22 (56) | ||
| Loss of expression | 0 (0) | 1 (4) | 0 (0) | 0 (0) | ||
| p53 percentage | ||||||
| < 15% | 40 (74) | 13 (52) | 1 (Ref) | 4 (9) | 1 (3) | 1 (Ref) |
| 15–40% | 12 (22) | 11 (44) | 2.69 (0.83–8.69) | 19 (41) | 11 (28) | 1.96 (0.11–35.10) |
| > 40% | 2 (4) | 1 (4) | 1.73 (0.10–29.16) | 23 (50) | 27 (69) | 4.54 (0.27–75.3) |
| Ki67 | ||||||
| < 20% | 25 (46) | 14 (56) | 1 (Ref) | 1 (2) | 4 (10) | 1 (Ref) |
| 20–50% | 24 (44) | 9 (36) | 0.65 (0.20–2.06) | 14 (30) | 12 (31) | 0.21 (0.01–3.80) |
| > 50% | 5 (9) | 2 (8) | 0.69 (0.09–5.22) | 31 (67) | 23 (59) | 0.17 (0.01–2.86) |
| TLR5 | ||||||
| Intensity < 2 | 41 (76) | 20 (80) | 1 (Ref) | 14 (38) | 17 (44) | 1 (Ref) |
| Intensity ≥ 2 | 13 (24) | 5 (20) | 0.83 (0.22–3.09) | 32 (62) | 22 (56) | 0.55 (0.17–1.80) |
| Percentage < 100% | 38 (70) | 12 (48) | 1 (Ref) | 18 (39) | 10 (26) | 1 (Ref) |
| Percentage 100% | 16 (30) | 13 (52) | 2.73 (0.88–8.49) | 28 (61) | 29 (74) | 2.06 (0.60–7.07) |
| Nuclear positivity ≤ 80% | 43 (80) | 19 (76) | 1 (Ref) | 18 (39) | 23 (59) | 1 (Ref) |
| Nuclear positivity > 80% | 11 (20) | 6 (24) | 1.23 (0.34–4.44) | 28 (61) | 16 (41) | 0.47 (0.15–1.47) |
Odds ratios were calculated using generalized linear mixed model where cases and controls were matched by age and sex. Studied immunohistochemical markers in premalignant (metaplasia and low-grade dysplasia) samples were based on HE-diagnoses of two expert gastrointestinal pathologists stratified by disease progression status
*Normal expression was based on weak to moderate intensity score
**Aberrant expression in p53 intensity included both loss of expression and overexpression
***Overexpression was based on the presence of high intensity score